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Johannes A. Romijn, and Alberto M. Pereira
Departments of Endocrinology and Metabolic Diseases (O.M.D., J.L., J.A.R., A.M.P.), and Clinical
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Department of Endocrinology (P.B.), University Hospital, 205 02 Malmo¨, Sweden; and Medical
Department M (J.O.J.), Aarhus University Hospital, DK-8000 Aarhus C, Denmark
Context: Dopamine agonists are the treatment of choice for prolactinomas and symptomatic
idiopathic hyperprolactinemia. However, the optimal treatment strategy and treatment duration
is not clear in all details.
Objective:Theaimof the studywas toassess theeffect ofdopamineagonistwithdrawal inpatients
with idiopathic hyperprolactinemia and prolactinomas.
Data Sources: PubMed, the Cochrane Library, the Web of Science, and EMBASE were searched
electronically. No restriction was made with respect to language.
Study Selection: Studies reporting the proportion of normoprolactinemic patients after with-
drawal of dopamine agonist or studies in which this proportion could be calculated were eligible.
Both observational studies and clinical trials were eligible. Nineteen studies were included in the
meta-analysis, with a total of 743 patients.
Data Extraction: Data extraction was performed by two reviewers independently.
Data Synthesis: The pooled proportion of patients with persisting normoprolactinemia after do-
pamine agonist withdrawal was 21% in a random effects model [95% confidence interval (CI),
14–30%; I2 81%). Stratified analysis showed higher proportions of treatment success in idiopathic
hyperprolactinemia (32%; 95% CI, 5–80%), compared with both microprolactinomas (21%; 95%
CI, 10–37%), andmacroprolactinomas (16%; 95%CI, 6–36%). In a randomeffectsmeta-regression
adjusting for cause of hyperprolactinemia, a longer treatment durationwas associatedwith treat-
ment success (P  0.015), whereas the use of cabergoline showed a trend of effect (P  0.07).
Conclusions:Thismeta-analysis showed thathyperprolactinemiawill recur afterdopamineagonist
withdrawal in a considerable proportion of patients. The probability of treatment success was
highest when cabergoline was used for at least 2 yr. (J Clin Endocrinol Metab 95: 43–51, 2010)
Dopamine agonists are the treatment of choice for pro-lactinomas and symptomatic idiopathic hyperpro-
lactinemia. Whether dopamine agonist treatment should
be lifelong has been a subject of debate (1). Since the in-
troduction of dopamine agonists more than 30 yr ago,
several studies have assessed the effect of dopamine ago-
nist withdrawal on the recurrence of hyperprolactinemia.
The debate has shifted from whether a dopamine agonist
can be stopped to the determination of the optimal timing
forwithdrawal (2). However, the optimal treatment strat-
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egy is not clear in all details, resulting in different treat-
ment policies (3). A recent study (4, 5) indicated that a
subgroup of hyperprolactinemic patients with a high like-
lihood of achieving remission can be identified on clinical
criteria. In 2006 the Pituitary Society published consensus
guidelines (6) that summarized these controversies.
To assess the effect of dopamine agonist withdrawal in
patients with idiopathic hyperprolactinemia and prolacti-
nomas inmoredetail,weperformeda systematic reviewof
the literature. The primary aim was to estimate the pooled
proportion of patients with persistent normoprolactinemia
after withdrawal of dopamine agonists in a meta-analysis.
The secondaimwas todetermine factors influencing the suc-
cess of treatment outcome in a sensitivity analysis.
Materials and Methods
Eligibility criteria
Themain outcome of the present analysis was the proportion
of patientswithpersistingnormoprolactinemia afterwithdrawal
of dopamine agonist treatment in idiopathic hyperprolactinemia
and prolactinomas. Studies reporting the proportion of normo-
prolactinemic patients after withdrawal of dopamine agonist or
studies inwhich this proportion could be calculatedwere eligible
for inclusion in this meta-analysis. The assessment of recurrence
of hyperprolactinemia was based only on prolactin levels, irre-
spective of clinical symptoms. Both observational studies and
clinical trials were eligible. There were no restrictions with re-
spect to the sort of dopamine agonist.
Studies were eligible for inclusion in this review if they ful-
filled the following criteria:
1. The normal reference values of prolactin had to be reported.
2. Duration of dopamine agonist treatment was at least 3
months, and during the treatment period normoprolactinemia
had to be attained.
3. Follow-up period for patients with persisting normopro-
lactinemia after treatment withdrawal was at least 6 months.
4. The maximum proportion of pretreatment with radio-
therapy in patients assessed for the effect of dopamine agonist
withdrawal was set at 20%. The reason for this constraint is
that the effect of radiotherapy on hyperprolactinemia can be
delayed for many years. Therefore, radiotherapy is a con-
founder in the assessment of the effect of dopamine agonist
withdrawal.
5. Variables as age, sex, type of dopamine agonist, and
treatment duration had to be reported. If only a subgroup of
a larger cohort was withdrawn from dopamine agonist treat-
ment, these parameters were extracted for this subgroup only.
If, however, these parameters were not reported for the sub-
group separately, the parameters of the total cohort were ex-
tracted as a proxy for the subgroup. The latter condition was
only permitted if the minimum percentage of patients in the
study cohort who attained normoprolactinemia during treat-
ment and subsequently stopped treatment was at least 75% of
the total study group. In this way, the variables of the total
cohort should be a reliable estimate of the variables of those
who attained normoprolactinemia during treatment and sub-
sequently stopped treatment.
6. There should be no (partial) duplication of cohorts. If,
nonetheless, partial duplication was present, the largest cohort
was included.
If the entire cohort did not fulfill the eligibility criteria, the
included cohort was restricted to eligible patients. However, this
was only possible in case the study provided data and outcomes
on individual patients or if data and outcomes were shown ac-
cording to subgroups; i.e., if possible, the cohort was restricted
to patients without radiotherapy, nonpregnant during follow-
up, and with a normalized prolactin before withdrawal of the
medication.
Search strategy
We searched the PubMed, the Cochrane Library, the Web of
Science, and EMBASE databases for publications in any lan-
guage examining the effect of withdrawal of dopamine agonists
on the recurrence of hyperprolactinemia. The search was re-
stricted by date of publication from 1970 onward because do-
pamine agonists were not available for the treatment of hyper-
prolactinemia before 1970. For details of the search strategy, see
the Appendix (published as supplemental data on The Endocrine
Society’s JournalsOnlineweb site at http://jcem.endojournals.org).
Searches were performed in July 2008. In addition, the ref-
erences of relevant articles were checked for additional articles.
Abstracts ofmeetings and unpublished results were not included
in the analysis. Therewas no restrictionwith respect to language.
Data review and data analysis
Initial selection of studies by title and abstractwas carried out
by one reviewer (J.L.). These studies were retrieved for full as-
sessment. This assessment and subsequent data extraction were
performed by two independent reviewers (J.L. and O.M.D.).
Disagreements were resolved by consensus. Whenever possible,
the study cohort was stratified by cause of hyperprolactinemia:
idiopathic hyperprolactinemia and hyperprolactinemia caused
by micro- and macroprolactinomas, respectively. The provided
reference ranges of the individual studies were used to determine
the presence of hyper and normoprolactinemia, despite the fact
that in a few studies the authors defined remission as mild hy-
perprolactinemia without symptoms. All prolactin levels in the
present meta-analysis were expressed as micrograms per liter.
The conversion factor for prolactin levels frommilliunits per liter
to micrograms per liter used was 1:30 (5), because we were not
able to acquire all conversion factors for the various assays. For
assessment of recurrence of hyperprolactinemia, the unit used by
the authors was used, not the converted levels. For studies re-
porting outcomes for several time intervals, the last point in time
was chosen for data extraction. For determination of tumor re-
gression during dopamine agonist treatment, results from mag-
netic resonance imaging (MRI) and computed tomography (CT)
were taken into account, not from conventional x-rays. For all
studies, the number of pregnant patients during follow-up was
extracted from the article if possible.
The main outcome of the meta-analysis was the weighted
average of the proportion of patients with persisting normo-
prolactinemia after withdrawal of dopamine agonist therapy.
The individual studies were weighted according to the inverse
of the squared SE. The I2 test was used to check for quantitative
heterogeneity (7). This measures the proportion of inconsis-
tency between the studies that cannot be explained by chance
alone.
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We performed the analyses stratified by causes of hyperpro-
lactinemia (idiopathic hyperprolactinemia, microprolactinomas
and microprolactinomas), the type of dopamine agonist, and
treatment duration (up to and including24monthsvs.more than
24 months). Random effects meta-regression was performed to
study the influence of treatment duration and dopamine agonist
preparation on persisting normoprolactinemia.
Statistical analyses were done in ComprehensiveMeta-Anal-
ysis (version 2.0; Biostat, Englewood, NJ) and Stata (version
10.0; Stata Corporation, College Station, TX).
Results
Literature search (Fig. 1)
The initial search in the databases resulted in a total of
968 articles (543 in PubMed, 29 in Cochrane Library, 84
in Web of Science, and 312 in EMBASE). Of these 968
studies, 754 were unique without duplications. We ex-
cluded685papers basedon title andabstract.A total of 69
potentially relevant papers were retrieved for full assess-
ment. Of these studies, 31 were excluded from further
analysis because the studies did not contain original data
on withdrawal of dopamine agonists in hyperprolactine-
mia. We were unable to obtain one study (8).
In 40 studies, a detailed assessment with respect to the
eligibility criteriawas performed. Twenty studieswere ex-
cluded from further analysis because these did notmet one
or more of the eligibility criteria (4, 9–28). Two studies
partially described the same cohort (4, 5); from these, the
study representing the extension was included (5). Con-
sequently, a total of 19 studieswere included in thepresent
review (5, 29–46).
For some studies the following subgroups were not in-
cluded: microprolactinomas treated with bromocriptine
(38) and macroprolactinomas (31, 33, 36). Reasons for
exclusions of these subgroups were the application of ra-
diotherapy in a large proportion of the subgroup (31, 33,
36), and a duration of follow-up after withdrawal in the
subgroup shorter than 3 months (38). In two studies,
patients were assessed twice after treatment with two
different dopamine agonists. To prevent multiplicity of
patients in the meta-analysis from these two studies,
only one of the assessed treatments was included. In one
study with a crossover design, only the results for caber-
goline, but not for treatment with quinagolide, were
included because during treatment with quinagolide
two patients were nonevaluable (35). In a second study,
only the outcomes after the first treatment, i.e. quinagolide,
were included (32). Of all included studies, three studies
were retrieved after inspection of the references of rel-
evant literature.
Study characteristics
Details of the 19 included studies are summarized in
Table 1. Studies on persisting normoprolactinemia after
withdrawal of dopamine agonistswere publishedbetween
1979 and 2007. In nine studies, patients were treated ac-
cording to a prespecified protocol (5, 30, 32, 34, 35, 37,
38, 40, 41). The number of included patients per study
ranged from 2 to 221. The total number of patients in-
cluded in thismeta-analysiswas 743.Therewere stratified
data available for a total of 49 patients with idiopathic
hyperprolactinemia, 353 with microprolactinomas, and
159 with macroprolactinomas. Idiopathic hyperprolactine-
mia was defined by authors as an unexplained hyperp-
rolactinemia in the presence of normal CT orMRI (5, 35,
38). In none of these three studies was macroprolactine-
mia explicitly ruled out. In three studieswith a total of 182
patients, the patients could not be separated with respect
to different etiology. In two studies, a considerable pro-
portion of patients were pregnant during follow-up: 43%
(42) and 30% (29). In one study, the data for analysis
could be restricted to nonpregnant patients (30). In a few
other studies one (5, 34, 40) or two (41) patients became
pregnant during follow-up.
Meta-analysis (Table 2)
The proportion of patients with persistent normopro-
lactinemia after withdrawal of dopamine agonists rangedFIG. 1. Summary of study assessment and exclusion stages.
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from 0 to 74%. This highest proportion of 74% was ob-
served in a series with idiopathic hyperprolactinemia
treated with cabergoline. The pooled proportion of pa-
tientswith persisting normoprolactinemia after dopamine
agonist withdrawal was 21% in a random effects model
[95% confidence interval (CI), 14–30%; I2 81%].
Sensitivity analysis (Table 2)
Restriction of the analysis to four studies using caber-
goline as the only treatment showed a pooled proportion
persisting normoprolactinemia of 35% (random effects
model, 95% CI, 19–56%). In studies using bromocrip-
tine, the proportion persisting normoprolactinemia was
lower (20%; 95% CI, 16–26%). Stratified analysis ac-
cording to cause of hyperprolactinemia showed higher
proportions of treatment success in idiopathic hyperpro-
lactinemia (32%; 95% CI, 5–80%) compared with both
microprolactinomas (21%; 95% CI, 10–37%) and mac-
roprolactinomas (16%; 95% CI, 6–36%). Higher pro-
portions of persisting normoprolactinemia were shown in
studies with treatment duration longer than 24 months
(34%; 95% CI, 19–52%), compared with studies with
shorter treatment duration (16%; 95%CI, 11–22%). Ex-
clusion from the analysis of two studies that used radio-
therapy in some patients (37, 42) showed persisting nor-
moprolactinemia in 39% (95% CI, 34–44%). Studies
in which 50% tumor reduction was achieved in all pa-
tients before stopping the dopamine agonist showed
persisting normoprolactinemia in 55% (95% CI, 36–
73%). Excluding two studies with a considerable pro-
portion of pregnant patients during follow-up (29, 42)
showed persisting normoprolactinemia in 20% (95%
CI, 12–31%). In studies with a prespecified protocol,
the treatment success was 18% (95%CI, 9–31%) using
a random effects model (I2 84%).
In a random effectsmeta-regression adjusting for cause
of hyperprolactinemia, longer treatment duration was as-
sociated with higher proportion of persisting normopro-
lactinemia (P  0.015), whereas the use of cabergoline
showed a trend of effect (P  0.07).
Exclusion of the study of Colao et al. (5) from the anal-
ysis decreased both the treatment success rates and the
heterogeneity for idiopathic hyperprolactinemia (17%; I2
0%), microprolactinomas (19%; I2 39%), and macro-
prolactinomas (12%; I2 31%). This decreasing heteroge-
neity showed that from a statistical point of view, the
results from that particular study were outliers in relation
to the results of the other studies.
Discussion
The present systematic review andmeta-analysis was per-
formed to estimate the pooled proportion of patients with
persistent normoprolactinemia afterwithdrawal fromdo-
pamine agonists. The study showed that withdrawal was
associated with persisting normoprolactinemia in only
21% of all patients. Success rates were higher in patients
treated for idiopathic hyperprolactinemia, after treatment
with cabergoline, and in patients with treatment duration
of more than 2 yr.
Randomized controlled studies comparing different
withdrawal strategies after successful treatment of hyper-
prolactinemia are lacking. In 2006, the Pituitary Society
provided guidelines as practical clinical tools for the rou-
tine clinical care. These guidelines were mainly based on a
landmark study by Colao et al. (4) that demonstrates that
dopamine agonist treatment indeed can be successfully
withdrawn in a considerable proportion of patients, pro-
vided that they fulfilled selected clinical criteria, such as
significant tumor reduction on radiological imaging and a
prolonged period of normoprolactinemia during treat-
ment. The first study that tested the practical applicability
of these 2006 Pituitary Society recommendations (6) was
TABLE 2. Persisting normoprolactinemia after withdrawal of dopamine agonists
No. of
studies
Fixed effects
model (95% CI) I2
Random effects
model (95% CI)
Overall effect 19 35% (31–39) 81% 21% (14–30)
Dopamine agonist
Cabergoline 4 54% (47–60) 85% 35% (19–56)
Bromocriptine 12 20% (16–26) 20% 20% (14–28)
Cause of hyperprolactinemia
Idiopathic hyperprolactinemia 3 53% (36–70) 85% 32% (5–80)
Microprolactinoma 13 40% (34–46) 84% 21% (10–37)
Macroprolactinoma 8 37% (29–46) 68% 16% (7–36)
Treatment duration
24 months 12 16% (11–22) 0% 16% (11–22)
24 months 7 40% (35–45) 91% 34% (19–52)
Prespecified protocol
Yes 9 45% (39–51) 84% 18% (9–31)
No 10 23% (19–28) 11% 24% (18–30)
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recently published (47). In that study, the estimated 18-
month risk of recurrence was 63% in a cohort of 46 se-
lected normoprolactinemic patients previously treated
with cabergoline for at least 2 yr. These data exemplify the
clinical dilemma: apparently it is indeedpossible in routine
clinical practice to successfully withdraw selected patients
from dopamine agonist treatment, but the likelihood of
success is not easily predicted in individual patients.
In agreement, in thepresent systematic review, themain
limitationswere theheterogeneityof includedpatients and
treatment regimes. These studies differed markedly with
respect to the causes of hyperprolactinemia, the treatment
before the start of the dopamine agonists, and the type and
duration of dopamine agonist therapy. Despite these
sources of heterogeneity, the proportion of patients with
persisting normoprolactinemia after withdrawal of dopa-
mine agonistswas lower than 30% in themajority of stud-
ies.Only three studies reportedahigher success rate (5, 36,
46), with a maximum of 74% in patients with idiopathic
hyperprolactinemia (5).
It should be noted that the pooled proportion of treat-
ment success is slightly overestimated in the current meta-
analysis, because studies with success rates of zero are
transformed to avoid zero cells for statistical purposes.
Moreover, the pooled proportion is not an accurate re-
flection of treatment success in all patients with either
hyperprolactinemia or prolactinomas, considering that
most studies reported withdrawal for only a selected
group of patients.
A sensitivity analysis showed that the study with the
highest success rate may be viewed as an outlier from a
statistical perspective. How does this particular study dif-
fer from the remaining ones? Of note, the duration of
dopamine agonist treatment was not extremely long com-
pared with other studies. However, the study from Colao
et al. (5) differswith respect to two important aspects from
all other included studies. First, before withdrawal, the
dose was reduced to a minimum level and not abruptly
stopped. Second, all patients fulfilling criteria for with-
drawal (i.e. tumor regression of 50% on imaging and
normoprolactinemia) continued treatment for another 12
months after fulfilling these criteria. In accordance, in an-
other study with persistent normoprolactinemia in more
than half of the microprolactinomas, dopamine agonist
treatmentwas explicitly continued several years after nor-
malization of prolactin levels (45). Because that study
comprised only seven patients in whom the effect of with-
drawal could be adequately assessed, the overall effect of
that study for the currentmeta-analysis was small. A third
aspect that could have contributed to the success rates in
the study from Colao et al. (5) is the use of cabergoline,
which is known to be the most potent of currently avail-
able dopamine agonists (48).
One limitation of the study fromColao et al. is that the
included patients were clearly selected. From 381 newly
diagnosed patients with hyperprolactinemia, 221 (58%)
patients were included in the study (5). The patients who
were not included can be supposed to have a less favorable
outcome with respect to persistent normoprolactinemia
afterwithdrawalofdopamineagonists.This is a limitation
for the external validity of the study results (49). The prior
probability of a newly diagnosed patient with a prolacti-
noma that the disease will be in remission after treatment
with a dopamine agonist will therefore be lower than the
proportions of treatment success reported in that study.
What are the clinical implications of the present meta-
analysis? Our study demonstrates that treatment with
cabergoline for more than 2 yr is associated with the best
outcome. Although it seems reasonable first to reduce the
cabergoline dose before withdrawal, this was only proto-
colized in one study (5). In addition, although observa-
tional studies have not reported clinical relevant cardiac
valve disease after treatmentwith cabergoline for prolacti-
nomas, the findings obtained with much higher cumula-
tive doses of cabergoline in Parkinson patients underscore
that unnecessary prolongation of treatment is undesirable
(50–52). Finally, a withdrawal trial in individual patients
is unlikely to negatively affect long-term outcome.
In conclusion, this meta-analysis showed that hyper-
prolactinemia will recur after dopamine agonist with-
drawal in a considerable proportionof patients. Theprob-
ability of treatment success is highest when cabergoline is
used for at least 2 yr.
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